All In Biotech

Drug Trial Radar · NCT00377572

Inner-City Anti-IgE Therapy for Asthma

Inner-City Anti-IgE Therapy for Asthma (ICAC-08)

Last checked: Nov 19, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 419 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

419

Actual

Start

Oct 2006

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Sponsor type
NIH
Collaborators
Inner-City Asthma Consortium
First posted
Sep 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if adding omalizumab to standard asthma treatment results in a safer, more effective, and longer lasting asthma treatment strategy than standard treatment alone, in inner-city children with mild to severe asthma.

Conditions

  • Asthma

Interventions

  • omalizumabBiological

    Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.

  • omalizumab placeboBiological

    Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Number of Asthma Symptom DaysTime frame: Weeks 12-60: 12 months of assessments starting 12 weeks after the initiation of study treatment.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona Health Sciences Center

    Tucson, Arizona

  • National Jewish Medical and Research Center

    Denver, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Memorial Hospital

    Chicago, Illinois

  • Boston University School of Medicine

    Boston, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • Rainbow Babies and Children's Hospital

    Cleveland, Ohio

  • University of Texas Southwestern Medical Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.